HeartWare International

The struggles at Heartware International continue as the company saw continued year-over-year losses in the second quarter of 2016.

Medtronic announced Monday that it will buy Framingham's Heartware International for $1.1 billion as the Dublin-based company seeks to expand its heart failure portfolio.

Revenue for Framingham's HeartWare International fell in 2015 as the company invested in studies to move towards new product deployment.

A class action lawsuit has been filed against HeartWare International, alleging that company officials misled shareholders as to the viability of a new technology by saying that the company had adequately addressed concerns by U.S. Food and Drug Administration revolving around their technology.

HeartWare International Inc. has announced it is backing out of a $929 million dollar purchase of Israeli company Valtech Cardio to concentrate on its core ventricular assist device business.

Framingham-based HeartWare International Inc., a medical device company specializing in the treatment of heart failure, continued to see its stock price decline Wednesday after a 35-percent dive Tuesday.

HeartWare International has agreed to acquire Valtech Cardio, and through that deal, the Framingham-based medical device firm sees a big opportunity to expand its reach in the structural heart market, according to a statement issued this week.

Framingham-based HeartWare International has received approval to market an implanted heart device in Canada.

Driven by what it termed “record sales” of it its Ventricular Assist Systems, Framingham-based HeartWare International on Thursday announced its run of solid revenue performance had extended to the third quarter.

Federal regulators released a letter that accuses Framingham-based HeartWare International of design and software malfunctions that might have resulted in serious injuries and death.